The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

SIMPLE SUMMARY: Over the last few years, CAR-T cells have arisen as one of the most promising immunotherapies against relapsed or refractory hematological cancers. Despite their good results in clinical trials, there are some limitations to overcome, such as undesirable side-effects or the restraint...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Lara, Santos, Silvia, Vesga, Miguel Angel, Carrascosa, Tomas, Garcia-Ruiz, Juan Carlos, Pérez-Martínez, Antonio, Juan, Manel, Eguizabal, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582420/
https://www.ncbi.nlm.nih.gov/pubmed/34771581
http://dx.doi.org/10.3390/cancers13215418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582420/
https://www.ncbi.nlm.nih.gov/pubmed/34771581
http://dx.doi.org/10.3390/cancers13215418

Ejemplares similares